Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: a real world observational study

摘要: Disclosures Linda Kemp has no conflict of interest to declare. John Haughney received some or all the following: reimbursements for attending symposia; fees speaking and organizing educational events; funds research; consulting; from following pharmaceutical companies: AstraZeneca, Boehringer-Ingelheim, Glaxo Smith Kline, Merck, Sharp Dohme, Mundipharma, Novartis, Nycomed, Sanofi Aventis Teva. He holds stocks shares. relationship with tobacco industry. Professor Neil Barnes lectured consulting AstraZeneca, GlaxoSmithKline, Chiesi, Cipla, NAPP. Professor had research grants Astra-Zeneca, GlaxoSmithKline Novartis which have gone into departmental funds. Erika Sims worked on projects funded by Schering Plough, Merck & Co., Inc., Teva, funding attend conferences. Julie von Ziegenweidt declare. Elizabeth V. Hillyer done freelance writing work Aerocrine, Teva Sante. Amanda J. Lee receives payment statistical consultancy through independent company, Thorpe Respiratory Research. Alison Chisholm declare David Price consultant arrangements Boehringer Ingelheim, Dey Pharmaceuticals, Sharpe Schering-Plough, his team support in respiratory disease organizations: UK National Health Service, Pfizer, spoken for: